XNCR Xencor Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1326732 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.8%
TTM net income YoY15.1%
TTM EPS YoY9.8%
Revenue 3-yr CAGR11.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-72.7%
Net margin-58.8%
FCF margin-88.0%
EBITDA margin-67.9%
Returns
ROE-19.9%
ROA-14.4%
ROIC (approx.)-17.4%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets27.3%
Debt / equity0.17x
Current ratio6.54x
Interest coverage-6.19x
Cash quality & payout
Operating cash flow / net income1.46x
Accruals ratio6.6%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $125.58M | $110.49M |
| R&D expense | $239.43M | $227.69M |
| SG&A expense | $63.64M | $61.22M |
| Operating income | -$177.50M | -$178.41M |
| Interest expense | $31.93M | $36.64M |
| Pretax income | -$89.63M | -$234.92M |
| Income tax | $2.50M | $1.62M |
| Net income | -$91.92M | -$232.62M |
| EBITDA | -$166.99M | -$166.30M |
| EPS (basic) | -1.24 | -3.58 |
| EPS (diluted) | -1.24 | -3.58 |
| Weighted avg. shares (diluted) | 74.24M | 65.04M |
| Banking | ||
| Net interest income | — | $31.93M |
| Balance sheet | ||
| Cash & equivalents | $54.07M | $41.26M |
| Receivables | $29.30M | $60.85M |
| Current assets | $599.82M | $577.60M |
| PP&E, net | $53.31M | $59.80M |
| Intangibles | $8.38M | $18.48M |
| Total assets | $875.50M | $951.95M |
| Current liabilities | $95.91M | $87.43M |
| Short-term debt | $43.27M | $48.45M |
| Long-term debt | $76.48M | $115.16M |
| Total debt | $119.75M | $163.61M |
| Total liabilities | $239.91M | $277.92M |
| Shareholders' equity | $635.59M | $677.61M |
| Net debt | $65.68M | $122.34M |
| Shares outstanding | 71.87M | 70.26M |
| Cash flow statement | ||
| Operating cash flow | -$135.12M | -$202.19M |
| Capital expenditure | $3.15M | $6.10M |
| Free cash flow | -$138.27M | -$208.28M |
| Investing cash flow | $139.99M | -$7.87M |
| Financing cash flow | $8.23M | $197.15M |
| Depreciation & amortization | $10.51M | $12.11M |
| Stock-based compensation | $43.23M | $53.28M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.